{"id":"W2732548543","doi":"10.1111/bjh.14787","title":"Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: <scp>ELOQUENT</scp>‐2 follow‐up and <i>post‐hoc</i> analyses on progression‐free survival and tumour growth","year":2017,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"AbbVie Biotherapeutics; Bristol-Myers Squibb","keywords":"Lenalidomide; Medicine; Dexamethasone; Hazard ratio; Internal medicine; Multiple myeloma; Progression-free survival; Post-hoc analysis; Oncology; Interim analysis; Refractory (planetary science); Gastroenterology; Surgery; Chemotherapy; Randomized controlled trial; Confidence interval; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002877062,0.0006997059,0.001499334,0.0002892312,0.0002445392,0.0007097303,0.0005426808,0.0005455815,0.002266011],"category_scores_gemma":[0.001304187,0.0003033428,0.001727777,0.0004088784,0.0004258342,0.0006389776,0.0003965642,0.001364371,0.0003624862],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001084556,"about_ca_system_score_gemma":0.00102756,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008837327,"about_ca_topic_score_gemma":0.002547939,"domain_scores_codex":[0.9991453,0.000389952,0.00004419508,0.0001552292,0.0001192288,0.0001460996],"domain_scores_gemma":[0.9990205,0.0002216343,0.0003362041,0.0001099218,0.0000632015,0.0002485098],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8817261,0.006366497,0.02831502,0.0005075744,0.003471163,0.0001692882,0.0001062203,0.002178026,0.008112895,0.00009692531,0.001792514,0.06715777],"study_design_scores_gemma":[0.3105837,0.3808625,0.2795363,0.0001582684,0.00574563,0.0005196893,0.0001265766,0.004139192,0.008856222,0.0005855249,0.008798279,0.00008821274],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945945,0.001876721,0.0003622095,0.0002067643,0.00004726019,0.0004150491,0.001632972,0.00003119903,0.0008332704],"genre_scores_gemma":[0.9935378,0.0004889165,0.0005644549,0.0003388622,0.00007903636,0.0004269859,0.003402158,0.00001367246,0.001148019],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002877062,"threshold_uncertainty_score":0.01521552,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07180174197422885,"score_gpt":0.3709442577312493,"score_spread":0.2991425157570205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}